ReviewMolecular therapy. Methods & clinical development2025
Membrane-modified lipid nanoparticles for RNA delivery.
Review in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- RNA Therapeutics Targeting Skeletal Muscle: Emerging Antisense and Gene-Modifying Strategies.Biomolecules · 2026Review
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
- Functionalized Lipid Nanoparticles for Targeted RNA Delivery in Immune and Inflammatory Diseases.Biomedicines · 2026Review
- Lipid nanoparticles for cell and gene therapy.Molecular therapy. Advances · 2026Article
- MicroRNAs as Emerging Therapeutic Targets Modulating the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2025Review
- Physiological Barriers to Nucleic Acid Therapeutics and Engineering Strategies for Lipid Nanoparticle Design, Optimization, and Clinical Translation.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ribonucleic acid (RNA)-mediated gene regulation is being widely investigated in preclinical and clinical studies owing to its immense potential for treating a broad spectrum of medical conditions. Because unmodified RNA molecules are rapidly degraded and cleared from circulation, carriers such as lipid nanoparticles (LNPs) are used to protect them, deliver them to target tissues, and facilitate their cellular entry and endosomal escape. However, most LNPs are trafficked to the liver upon intravenous administration, so new approaches are being explored to facilitate extrahepatic delivery. Recent studies suggest that modifying RNA-loaded LNPs with cell-derived phospholipid membranes can alter their biodistribution, cellular entry, and gene regulation potency, resulting in improved therapeutic outcomes. This review discusses the status of membrane-modified LNPs for RNA delivery, highlights key design criteria for these systems, and provides perspectives on the path toward clinical implementation. With further development, these exciting tools could enable RNA-based therapies to realize their full clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.